These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 34866828)
1. Cytokine Storm and Immunomodulation in COVID-19. Rangappa P Indian J Crit Care Med; 2021 Nov; 25(11):1288-1291. PubMed ID: 34866828 [TBL] [Abstract][Full Text] [Related]
2. Off-label Use of Itolizumab in Patients with COVID-19 ARDS: Our Clinical Experience in a Dedicated COVID Center. Kumari P; Kumar A; Sinha C; Kumar A; Singh PK; Arun SK Indian J Crit Care Med; 2021 Apr; 25(4):467-469. PubMed ID: 34045817 [TBL] [Abstract][Full Text] [Related]
8. Tocilizumab and COVID-19. Chaudhry D; Singh PK Indian J Crit Care Med; 2020 Sep; 24(9):741-743. PubMed ID: 33132549 [TBL] [Abstract][Full Text] [Related]
9. Present and future treatment strategies for coronavirus disease 2019. Elekhnawy E; Kamar AA; Sonbol F Futur J Pharm Sci; 2021; 7(1):84. PubMed ID: 33850936 [TBL] [Abstract][Full Text] [Related]
10. Anti-cytokine Therapy in Hospitalized Patients with COVID-19: The Jury is Out. Garg SK Indian J Crit Care Med; 2022 Oct; 26(10):1069-1071. PubMed ID: 36876195 [No Abstract] [Full Text] [Related]
11. Tocilizumab Use in COVID-19 Cytokine-release Syndrome: Retrospective Study of Two Centers. Nasa P; Singh A; Upadhyay S; Bagadia S; Polumuru S; Shrivastava PK; Sankar R; Vijayan L; Soliman MA; Ali A; Patidar S Indian J Crit Care Med; 2020 Sep; 24(9):771-776. PubMed ID: 33132558 [TBL] [Abstract][Full Text] [Related]
12. Antirheumatic Drugs against COVID-19 from the Perspective of Rheumatologists. Kawazoe M; Kihara M; Nanki T Pharmaceuticals (Basel); 2021 Dec; 14(12):. PubMed ID: 34959657 [TBL] [Abstract][Full Text] [Related]
13. Toll-like receptors in sepsis-associated cytokine storm and their endogenous negative regulators as future immunomodulatory targets. Kumar V Int Immunopharmacol; 2020 Dec; 89(Pt B):107087. PubMed ID: 33075714 [TBL] [Abstract][Full Text] [Related]
14. Tocilizumab in COVID-19: Is the Temptation Worthwhile? Gupta S; Tomar DS Indian J Crit Care Med; 2021 Mar; 25(3):247-248. PubMed ID: 33790498 [No Abstract] [Full Text] [Related]
15. Cytokine storm modulation in COVID-19: a proposed role for vitamin D and DPP-4 inhibitor combination therapy (VIDPP-4i). Pinheiro MM; Fabbri A; Infante M Immunotherapy; 2021 Jun; 13(9):753-765. PubMed ID: 33906375 [TBL] [Abstract][Full Text] [Related]
16. A Multicenter Questionnaire-based Study to Know the Awareness and Medical Treatment Plan of Physicians Involved in the Management of COVID-19 Patients. Maddani SS; Chaudhuri S; Deepa HC; Amara V Indian J Crit Care Med; 2020 Oct; 24(10):919-925. PubMed ID: 33281315 [TBL] [Abstract][Full Text] [Related]
17. Immunomodulation and COVID-19: Is There a Winning Combination? Samavedam S Indian J Crit Care Med; 2020 Nov; 24(11):1015-1017. PubMed ID: 33384504 [TBL] [Abstract][Full Text] [Related]
18. Early identification of COVID-19 cytokine storm and treatment with anakinra or tocilizumab. Langer-Gould A; Smith JB; Gonzales EG; Castillo RD; Figueroa JG; Ramanathan A; Li BH; Gould MK Int J Infect Dis; 2020 Oct; 99():291-297. PubMed ID: 32768693 [TBL] [Abstract][Full Text] [Related]
19. Severe Thrombocytopenia in COVID-19: A Conundrum in Dengue-endemic Areas. Adarsh MB; Abraham A; Kavitha P; Nandakumar MM; Vaman RS Indian J Crit Care Med; 2021 Apr; 25(4):465-466. PubMed ID: 34045816 [TBL] [Abstract][Full Text] [Related]
20. Design of Clinical Trials Evaluating Ruxolitinib, a JAK1/JAK2 Inhibitor, for Treatment of COVID-19-Associated Cytokine Storm. Langmuir P; Yeleswaram S; Smith P; Knorr B; Squier P Dela J Public Health; 2020 Jul; 6(2):50-54. PubMed ID: 34467111 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]